selinexor + temozolomide

Selinexor + temozolomide is an investigational combination therapy consisting of two small molecule drugs: selinexor, a selective inhibitor of nuclear export, and temozolomide, an oral alkylating agent. Selinexor inhibits exportin 1 (XPO1), leading to the accumulation of tumor suppressor proteins in the nucleus and induction of apoptosis in cancer cells. Temozolomide methylates DNA at the O6 and N7 positions of guanine, resulting in DNA damage and cell death. The combination is being studied primarily for its potential to improve outcomes in patients with glioblastoma or other brain tumors by leveraging complementary mechanisms—selinexor’s disruption of nuclear-cytoplasmic transport may sensitize tumor cells to DNA-damaging agents like temozolomide[1][2][3][4][5]. Clinical trials are ongoing to determine safety, tolerability, optimal dosing schedules, and efficacy.

Other names

selinexor and temozolomideSEL+TMZ